Picture Berlin Partner Top News from HealthCapital Berlin-Brandenburg 650x100px

Document › Details

Reuters. (2/10/17). "News: BRIEF – Santhera Successfully Places 60 mln Swiss Francs Senior Convertible Bonds".

	Organisation	Santhera Pharmaceuticals Holding AG (SIX: SANN)
	Group	Santhera (Group)
	Product	investment banking
	Product 2	Raxone®
	Index term	Santhera–SEVERAL: credit, 201702–202202 senior unsecured convertible bonds CHF60m 5% due 202202

Original document
accessed by [iito] on 2017-02-11

Record changed: 2023-06-05

Picture Twist Bioscience We Do DNA 650x200px 1size

More documents for Santhera (Group)

[1] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
[2] Santhera Pharmaceuticals Holding AG. (6/20/23). "Press Release: Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties [Ad hoc announcement pursuant to Art. 53 LR]...
[3] Santhera Pharmaceuticals Holding AG. (1/4/22). "Press Release: Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region". Pratteln....
[4] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
[5] Santhera Pharmaceuticals Holding AG. (10/6/20). "Press Release: Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone". Pratteln....
[6] Santhera Pharmaceuticals Holding AG. (1/24/20). "Press Release: Santhera Appoints New Chief Financial Officer". Pratteln....
[7] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....
[8] Santhera Pharmaceuticals Holding AG. (12/14/18). "Press Release: Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license". Pratteln....
[9] Santhera Pharmaceuticals Holding AG. (12/12/18). "Press Release: Santhera Announces Financial Results for the First Nine Months of 2018". Pratteln....
[10] Santhera Pharmaceuticals Holding AG. (11/21/18). "Press Release: Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone". Pratteln & Allschwil....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]